Press Releases

GlobeNewswire, Inc.

NAARDEN, The Netherlands and MIAMI, Nov. 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for...

GlobeNewswire, Inc.

PRINCETON, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced that management will present at the Guggenheim...

GlobeNewswire, Inc.

NEW YORK and TORONTO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to improving the treatment landscape in mental health...

GlobeNewswire, Inc.

-- Strong U.S. launch momentum for IMCIVREE® (setmelanotide) for acquired hypothalamic obesity (HO) continues with more than 700 patient start forms as of September 30, 2026 -- -- Third quarter 2026 net product revenue from global sales of...

GlobeNewswire, Inc.

DALLAS, Nov. 03, 2026 (GLOBE NEWSWIRE) -- IMS Legal Strategies (IMS) announces a new expansion of its fast-growing Life Care Planning services and a continuation of its overall growth strategy, with the acquisition of Medical & Life Care...

GlobeNewswire, Inc.

DALLAS, Nov. 03, 2026 (GLOBE NEWSWIRE) -- IMS Legal Strategies (IMS) announces a new expansion of its fast-growing services, and a continuation of its overall growth strategy, with the acquisition of Medical & Life Care Consulting Services (MLCC),...

GlobeNewswire, Inc.

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for...

GlobeNewswire, Inc.

BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- altaFlow, the no-code document workflow automation platform owned and managed by airSlate, Inc., today announced findings from its 2026 research report, “Two Versions of the Truth”. A discount changed at...

EIN Presswire

A medical team in Dubai has successfully stopped severe epileptic seizures in an infant who had been experiencing 110 seizures a day DUBAI, UNITED ARAB EMIRATES, November 3, 2026 /⁨EINPresswire.com⁩/ -- A medical team in Dubai has successfully...

GlobeNewswire, Inc.

EINDHOVEN, the Netherlands, Nov. 03, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord...

GlobeNewswire, Inc.

Started dosing healthy volunteers with KRRO-121 in the Phase 1/2 clinical trial (ANCHOR) Expect to dose participants with Urea Cycle Disorders (UCDs) in the first half of 2027 Anticipate reporting interim data in the second half of 2027 Achieved...

GlobeNewswire, Inc.

-- Amendment revised royalty structure from low-to-mid-single digits to 1% on global net sales of Rhythm MC4R agonists, including setmelanotide, bivamelagon and RM-718 -- -- Rhythm to pay LG Chem additional fixed payments totaling $350 million...

GlobeNewswire, Inc.

Positive GFORCE-1 Phase 1 results showed MRT-8102 reduced key pathogenic drivers of atherosclerotic cardiovascular disease (ASCVD) to levels comparable to healthy volunteers across all three dose levels, with treatment-emergent adverse event rates...

Massachusetts Technology Collaborative

BOSTON – Jumping 22 positions, Massachusetts Technology Collaboration (MassTech) CEO Carolyn Kirk was ranked No. 54 by The Women's Edge at Friday’s 2026 Top 100 Women-Led Businesses in Massachusetts celebration.

GlobeNewswire, Inc.

BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral...

GlobeNewswire, Inc.

RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the treatment of advanced and resistant cancer,...

GlobeNewswire, Inc.

OXFORD, United Kingdom, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Oxford Brain Diagnostics (OBD), a pioneer in quantitative brain biology, today announced that it has won the Innovation Showcase at the 2026 CNS Summit in Boston.

GlobeNewswire, Inc.

SOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. (“Marea”), a subsidiary of Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage biotechnology company harnessing the...

GlobeNewswire, Inc.

- PDUFA target action date of May 27, 2027, following FDA acceptance of obexelimab BLA submission for the treatment of IgG4-RD in August 2026 - - Obexelimab MAA submitted to the EMA for the treatment of IgG4-RD - - New data presented at IgG4ward!...

GlobeNewswire, Inc.

Financing led by Viking Global Investors alongside a syndicate of venture philanthropy investors with deep expertise in epidermolysis bullosa Proceeds to support scale-up manufacturing, IND-enabling development of NvA-021, and advance the program...